Inactive Instrument
Company Vical Incorporated Nasdaq
Stocks
US9256022032
Biotechnology & Medical Research
Business description: Vical Incorporated
Sales by Activity: Vical Incorporated
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) |
|---|---|---|---|---|---|
Pharmaceuticals | 7.92M | 1.82M | 404K | 6.94M | 8.01M |
Geographical breakdown of sales: Vical Incorporated
| Fiscal Period: December | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) |
|---|---|---|---|---|---|
United States | 7.92M | 1.82M | 404K | 6.94M | 8.01M |
Executive Committee: Vical Incorporated
| Manager | Title | Age | Since |
|---|---|---|---|
Albert Marchio
CEO | Chief Executive Officer | 74 | 2023-10-01 |
Nancy Seretta
CTO | Chief Tech/Sci/R&D Officer | - | 2015-12-31 |
Aaron Fox-Collis
DFI | Director of Finance/CFO | - | 2022-05-31 |
Aron Aizenstat
PRN | Corporate Officer/Principal | - | - |
Sue Fattor
HRO | Human Resources Officer | - | - |
Composition of the Board of Directors: Vical Incorporated
| Director | Title | Age | Since |
|---|---|---|---|
Albert Marchio
CHM | Chairman | 74 | 2023-10-01 |
Company details: Vical Incorporated
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.59% | -3.35% | +52.37% | +93.70% | 69.54B | |
| -1.34% | -0.75% | +48.21% | +91.86% | 64.97B | |
| +0.30% | -0.69% | +52.56% | +10.23% | 26.51B | |
| -2.35% | -5.75% | -12.90% | +448.54% | 25.89B | |
| -8.37% | -12.43% | +2.08% | -16.71% | 25.64B | |
| -0.96% | +10.36% | +283.06% | +436.50% | 20.22B | |
| -0.51% | +0.23% | +35.77% | -18.70% | 19.98B | |
| -1.91% | -4.37% | +13.28% | +535.19% | 15.69B | |
| -1.47% | +0.68% | +45.51% | +143.08% | 13.49B | |
| Average | -2.02% | -1.93% | +57.77% | +191.52% | 31.33B | |
| Weighted average by Cap. | -1.93% | -1.50% | +53.73% | +151.51% |
